본문으로 건너뛰기
← 뒤로

[A Case of Pathological Complete Response Post‒Pembrolizumab Therapy for Recurrent Liver Metastasis of Ascending Colon Cancer].

1/5 보강
Gan to kagaku ryoho. Cancer & chemotherapy 📖 저널 OA 0% 2021: 0/1 OA 2022: 0/4 OA 2023: 0/4 OA 2024: 0/44 OA 2025: 0/134 OA 2026: 0/24 OA 2021~2026 2025 Vol.52(10) p. 729-731
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
laparoscopic right hemicolectomy for ascending colon cancer (pT4aN2aM0)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Subsequently, surgical resection of the liver metastasis revealed no residual tumor and pathological complete response was confirmed. The patient has remained recurrence‒free without further treatment.

Tanaka Y, Inazu D, Yamada M, Gyobu K, Takii M, Mayumi K

📝 환자 설명용 한 줄

A female patient in her 70s, underwent laparoscopic right hemicolectomy for ascending colon cancer (pT4aN2aM0).

이 논문을 인용하기

↓ .bib ↓ .ris
APA Tanaka Y, Inazu D, et al. (2025). [A Case of Pathological Complete Response Post‒Pembrolizumab Therapy for Recurrent Liver Metastasis of Ascending Colon Cancer].. Gan to kagaku ryoho. Cancer & chemotherapy, 52(10), 729-731.
MLA Tanaka Y, et al.. "[A Case of Pathological Complete Response Post‒Pembrolizumab Therapy for Recurrent Liver Metastasis of Ascending Colon Cancer].." Gan to kagaku ryoho. Cancer & chemotherapy, vol. 52, no. 10, 2025, pp. 729-731.
PMID 41139967 ↗

Abstract

A female patient in her 70s, underwent laparoscopic right hemicolectomy for ascending colon cancer (pT4aN2aM0). Eight courses of post‒operative adjuvant chemotherapy with CapeOX were administered. However, 1 year and 5 months post‒surgery, liver metastasis was observed. Following 1 course of FOLFIRI therapy and 1 course of FOLFIRI+bevacizumab therapy, high‒frequency microsatellite instability (MSI‒H) was detected, and pembrolizumab therapy was initiated. CT imaging revealed necrotic changes in the metastatic lesion while stable disease (SD) was maintained. After completing 28 courses of pembrolizumab therapy over 1 year and 9 months, the treatment was temporarily discontinued. One year and 3 months after discontinuation, the CEA level was elevated and the tumor was enlarged. Pembrolizumab therapy was resumed, and 5 additional courses were administered. Subsequently, surgical resection of the liver metastasis revealed no residual tumor and pathological complete response was confirmed. The patient has remained recurrence‒free without further treatment.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반